• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by SomaLogic Inc. (Amendment)

    2/14/23 7:59:43 AM ET
    $SLGC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Get the next $SLGC alert in real time by email
    SC 13G/A 1 eh230329918_13ga1-somalogic.htm AMENDMENT NO. 1

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)

     

    SomaLogic, Inc.

    (Name of Issuer)
     

    Common stock, $0.0001 par value per share

    (Title of Class of Securities)
     

    83444K105

    (CUSIP Number)
     
    December 31, 2022
    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

      ☐ Rule 13d-1(b)
      ☒ Rule 13d-1(c)
      ☐ Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out of a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended (the “Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

       

     

     

    CUSIP No. 83444K105 SCHEDULE 13G Page 2 of 5

     

     

    1

    NAME OF REPORTING PERSON

     

    Lawrence Marshall Gold

     
    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

     

    (a)  ☐

    (b)  ☐

    3

    SEC USE ONLY

     

     

     
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States

     

    NUMBER OF

    SHARES

    BENEFICIALLY OWNED

    BY EACH REPORTING

    PERSON

    WITH

    5

    SOLE VOTING POWER

     

    1,582,225

    6

    SHARED VOTING POWER

     

    -0-

    7

    SOLE DISPOSITIVE POWER

     

    1,582,225

    8

    SHARED DISPOSITIVE POWER

     

    -0-

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    3,627,197

     
    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     

    ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    1.9%

     
    12

    TYPE OF REPORTING PERSON

     

    IN

     

     

       

     

     

    CUSIP No. 83444K105 SCHEDULE 13G Page 3 of 5

     

     

    Item 1. (a) Name of Issuer:
         
        SomaLogic, Inc.
         
      (b) Address of Issuer’s Principal Executive Offices:
         
        2945 Wilderness Place, Boulder, CO 80301
         
    Item 2. (a) Name of Person Filing:
         
        This statement is filed on behalf of Mr. Lawrence Marshall Gold (the “Reporting Person”).
         
      (b) Address of Principal Business Office or, if none, Residence:
         
        The principal business address of the Reporting Person is:
         
        1033 5th Street, Boulder, CO 80302.
         
      (c) Citizenship:
         
        Mr. Gold is a citizen of the United States of America.
         
      (d)

    Titles of Classes of Securities:

     

        Common Stock, par value $0.0001 per share (“Common Stock”).
         
      (e) CUSIP Number:
         
        83444K105
         
    Item 3. If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a(n):
         
      Not applicable.
         
    Item 4.

    Ownership

     

    (a), (b) and (c)

       
     

    Mr. Gold may be deemed the beneficial owner of 3,627,197 share of Common Stock (1.9% of the outstanding shares of Common Stock) consisting of (i) 1,582,225 shares of Common Stock held directly, and over which he exercises sole voting and dispositive control and (ii) 2,044,972 shares of Common Stock held of record by the Lawrence M. Gold 2003 Irrevocable Trust, which he may be deemed to beneficially own. Mr. Gold disclaims beneficial ownership over such shares except to the extent of his pecuniary interest therein..

     

    Percentage ownership is based on 187,525,985 shares of common stock outstanding as of November 4, 2022, as reported in SomaLogic Inc.’s Quarterly Report on Form 10-Q filed with the SEC on November 15, 2022.

       
    Item 5. Ownership of Five Percent or Less of a Class.
       
     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☒.

     

     

     

     

    CUSIP No. 83444K105 SCHEDULE 13G Page 4 of 5

     

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.
       
      Not Applicable.
       
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.
       
      Not Applicable.
       
    Item 8. Identification and Classification of Members of the Group.
       
      Not Applicable.
       
    Item 9. Notice of Dissolution of Group.
       
      Not Applicable.
       
    Item 10. Certification.
       
     

    The Reporting Person hereby makes the following certification:

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

     

     

    CUSIP No. 83444K105 SCHEDULE 13G Page 5 of 5

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of their knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

    Dated: February 13, 2023

     

     

        /s/ Lawrence Marshall Gold  
        Lawrence Marshall Gold  

     

     

       

    Get the next $SLGC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SLGC

    DatePrice TargetRatingAnalyst
    10/5/2023$3.50 → $2.29Buy → Hold
    Jefferies
    9/25/2023$5.00 → $2.50Buy → Hold
    Canaccord Genuity
    2/1/2022$12.00Buy
    Stifel
    12/14/2021$19.00Buy
    Canaccord Genuity
    12/10/2021$16.00Buy
    Jefferies
    11/23/2021$18.00Outperform
    Cowen & Co.
    More analyst ratings

    $SLGC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • OncoHost Selected to Present in Oral Minisymposium at American Association of Cancer Research (AACR) Annual Meeting 2024

      Data to showcase PROphet® platform's machine learning models for predicting therapeutic benefit and immune-related adverse events in non-small cell lung cancer patients treated with immunotherapy BINYAMINA, Israel and CARY, N.C., March 5, 2024 /PRNewswire/ -- OncoHost, a technology company transforming the approach to precision medicine for improved patient outcomes, today announced it will be presenting new results at the American Association for Cancer Research (AACR) Annual Meeting taking place in San Diego, California from April 5-10, 2024. The oral presentation will feature insights from the company's PROPHETIC trial, to be delivered by Prof. Jarushka Naidoo, consultant medical oncologi

      3/5/24 4:35:00 PM ET
      $SLGC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Standard BioTools Stockholders Approve Merger with SomaLogic

      SOUTH SAN FRANCISCO, Calif., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health, today announced that its stockholders voted to approve all proposals required to be approved in connection with the pending merger with SomaLogic (NASDAQ:SLGC) at its Special Meeting of Stockholders. "We are pleased with the outcome of today's Special Meeting and thank our stockholders for their support for this merger," said Michael Egholm, PhD, President and Chief Executive Officer of Standard BioTools. "Together with SomaLogic, we will have an expanded platform to better serve our customers and we be

      1/4/24 10:23:06 PM ET
      $LAB
      $SLGC
      Biotechnology: Laboratory Analytical Instruments
      Industrials
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SomaLogic Stockholders Vote to Approve Standard BioTools Transaction at Special Meeting

      Stockholder Approval Represents Key Milestone Toward Completion of Standard BioTools Transaction Combination Will Create a Diversified Leader in Life Sciences Tools BOULDER, Colo., Jan. 4, 2024 /PRNewswire/ -- SomaLogic, Inc. (NASDAQ:SLGC) ("the Company"), a leader in proteomics technology, today announced that, based on the preliminary vote count provided by its proxy solicitors following the Company's Special Meeting of Stockholders (the "Special Meeting") held earlier today, SomaLogic stockholders voted to approve the transaction with Standard BioTools Inc. (NASDAQ:LAB) ("Standard BioTools"). The SomaLogic Board of Directors issued the following statement: We are grateful for the suppor

      1/4/24 9:44:00 PM ET
      $LAB
      $SLGC
      Biotechnology: Laboratory Analytical Instruments
      Industrials
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $SLGC
    SEC Filings

    See more
    • SEC Form 15-12G filed by SomaLogic Inc.

      15-12G - SomaLogic, Inc. (0001837412) (Filer)

      1/16/24 8:00:29 AM ET
      $SLGC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form EFFECT filed by SomaLogic Inc.

      EFFECT - SomaLogic, Inc. (0001837412) (Filer)

      1/12/24 12:15:06 AM ET
      $SLGC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form EFFECT filed by SomaLogic Inc.

      EFFECT - SomaLogic, Inc. (0001837412) (Filer)

      1/12/24 12:15:08 AM ET
      $SLGC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $SLGC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by SomaLogic Inc. (Amendment)

      SC 13G/A - SomaLogic, Inc. (0001837412) (Subject)

      1/29/24 5:25:49 PM ET
      $SLGC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form SC 13G/A filed by SomaLogic Inc. (Amendment)

      SC 13G/A - SomaLogic, Inc. (0001837412) (Subject)

      1/29/24 4:00:59 PM ET
      $SLGC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form SC 13D/A filed by SomaLogic Inc. (Amendment)

      SC 13D/A - SomaLogic, Inc. (0001837412) (Subject)

      1/9/24 5:16:22 PM ET
      $SLGC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $SLGC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • SomaLogic downgraded by Jefferies with a new price target

      Jefferies downgraded SomaLogic from Buy to Hold and set a new price target of $2.30 from $3.50 previously

      10/5/23 7:49:23 AM ET
      $SLGC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SomaLogic downgraded by Canaccord Genuity with a new price target

      Canaccord Genuity downgraded SomaLogic from Buy to Hold and set a new price target of $2.50 from $5.00 previously

      9/25/23 9:02:13 AM ET
      $SLGC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Stifel initiated coverage on SomaLogic with a new price target

      Stifel initiated coverage of SomaLogic with a rating of Buy and set a new price target of $12.00

      2/1/22 6:15:39 AM ET
      $SLGC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $SLGC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Taich Adam returned 48,425 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - SomaLogic, Inc. (0001837412) (Issuer)

      1/9/24 9:54:27 PM ET
      $SLGC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form 4 filed by Ryan Jason

      4 - SomaLogic, Inc. (0001837412) (Issuer)

      1/9/24 9:53:22 PM ET
      $SLGC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Roelke Alison Marie returned 17,143 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - SomaLogic, Inc. (0001837412) (Issuer)

      1/9/24 9:52:15 PM ET
      $SLGC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $SLGC
    Financials

    Live finance-specific insights

    See more

    $SLGC
    Leadership Updates

    Live Leadership Updates

    See more
    • SomaLogic Board Reiterates Value-Maximizing Transaction with Standard BioTools is in Best Interests of All Stockholders

      Continues to Recommend Stockholders Vote "FOR" Pending Merger ISS has Dismissed Madryn's Misleading Claims and Reaffirms that Stockholders Vote "FOR" the Merger BOULDER, Colo., Dec. 29, 2023 /PRNewswire/ -- SomaLogic, Inc. (NASDAQ:SLGC) ("the Company"), a leader in proteomics technology, today sent the following open letter to stockholders reiterating the Board's belief that the proposed transaction between SomaLogic and Standard BioTools is in the best interest of all stockholders. The full text of the letter is as follows: Dear Fellow Stockholders, We firmly believe that the value-maximizing transaction with Standard BioTools is the best path forward for SomaLogic and all of its stockhold

      12/29/23 8:42:00 AM ET
      $SLGC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • ISS Recommends SomaLogic Stockholders Vote "FOR" Proposed Merger with Standard BioTools

      BOULDER, Colo., Dec. 22, 2023 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in proteomics technology, today announced that Institutional Shareholder Services ("ISS") has recommended that SomaLogic stockholders vote "FOR" the pending merger with Standard BioTools at the company's Special Meeting of Stockholders to be held on January 4, 2024. In its "FOR" recommendation to SomaLogic stockholders, ISS noted1: The strategic rationale of combining two sub-scale companies in order to slow down cash burn and accelerate the path to profitability appears reasonable, particularly given the apparent overlap in the two companies' offerings and the estimated synergies in this transaction.…the all-sto

      12/22/23 6:47:52 PM ET
      $SLGC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SomaLogic Issues Letter to Stockholders Reiterating Recommendation for Value Maximizing Merger with Standard BioTools

      Combination Builds Scale and Accelerates Path to Profitability, Unlocking Significant Potential Value for SomaLogic Stockholders Madryn's Concerns are Not Based on Facts, and Madryn Selectively Ignores Risks in a Standalone Strategy and Potential Benefits of the Merger Urges Stockholders to Vote "FOR" Merger Ahead of Special Meeting of Stockholders on January 4, 2024 BOULDER, Colo., Dec. 21, 2023 (GLOBE NEWSWIRE) -- SomaLogic, Inc. (NASDAQ:SLGC) today issued an open letter to stockholders highlighting the value maximizing merger entered into with Standard BioTools (NASDAQ:LAB) on October 4, 2023. The Company also filed an investor presentation, which can be found on th

      12/21/23 8:00:00 AM ET
      $LAB
      $SLGC
      Biotechnology: Laboratory Analytical Instruments
      Industrials
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Madryn Asset Management, a Top Shareholder of SomaLogic, Issues Letter Regarding Opposition to the Company's Proposed Merger with Standard BioTools

      Files Preliminary Proxy Statement to Solicit Shareholders to Oppose the Merger Intends to Vote AGAINST the Conflict-Plagued and Excessively Dilutive Transaction, Which Stands to Unduly Benefit Certain Investors and Standard BioTools at the Expense of SomaLogic's Shareholders Notes the Current Premium for SomaLogic Shareholders, Based on the Deal's Exchange Ratio and Standard BioTools' Trading Price, is Only ~4.3% Underscores That SomaLogic Has Superior Alternatives to a Flawed Combination, Including a Standalone Path Leveraging its Considerable Cash Position and Strong Balance Sheet Madryn Asset Management, LP (collectively with its affiliates, "Madryn"), a holder of approximately 4

      12/12/23 5:31:00 PM ET
      $EXAS
      $ILMN
      $LAB
      $ME
      Medical Specialities
      Health Care
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SomaLogic Announces Chief Financial Officer Transition

      Appoints Eliot M. Lurier, CPA, as Interim Chief Financial Officer Reaffirms 2023 Financial Guidance BOULDER, Colo., June 06, 2023 (GLOBE NEWSWIRE) -- SomaLogic, Inc. (NASDAQ:SLGC), a leader in proteomics technology, today announced a Chief Financial Officer transition. Eliot M. Lurier, CPA, is joining the company as Interim CFO while the Company conducts a search for a permanent CFO. Shaun Blakeman has left the company, effective June 5, 2023. Mr. Lurier has over 35 years of experience in financial and leadership positions across the life science industry. He will report directly to the Interim CEO and immediately embed within the finance organization to ensure a seamless transiti

      6/6/23 4:05:00 PM ET
      $SLGC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SomaLogic Announces the Appointment of Biotech Veteran Troy Cox as Executive Chairman of the Board of Directors

      BOULDER, Colo. and SAN DIEGO, Oct. 17, 2022 (GLOBE NEWSWIRE) -- SomaLogic (NASDAQ:SLGC), a leader in AI data-driven proteomics technology, today announced the appointment of current board member and biotech veteran Troy Cox as Executive Chair to the company's Board of Directors. The current Chair, Chuck Lillis, will remain on the board. Changes are effective as of today, October 17, 2022. Mr. Cox brings over thirty years of experience in the life sciences and biopharmaceuticals industry to his expanded position as Executive Chair of the Board. Mr. Cox was the President and CEO of Foundation Medicine from early 2017 through the acquisition by Roche, valuing Foundation Medicine at $5.3 bill

      10/17/22 4:30:00 PM ET
      $SLGC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care